Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-08-31 | Reverse | 1:5 |
| 2023-03-20 | Reverse | 1:14 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$1.54 ▼ DOWN 3.75% (−$0.06)About CalciMedica, Inc.
https://www.calcimedica.com ↗CalciMedica, Inc. is a La Jolla-based biotech company developing CRAC channel inhibitors like Auxora to treat severe inflammatory diseases such as acute pancreatitis and kidney injury.
INDUSTRY
A PRODUCT CALCIMEDICA, INC. IS KNOWN FOR
Auxora™ is CalciMedica's IV small molecule CRAC channel inhibitor in clinical trials for treating severe inflammatory diseases like acute pancreatitis, with a pivotal trial underway after successful Phase 2 studies.
CalciMedica in 2025
CalciMedica Announces Collaboration with Telperian to Integrate Artificial Intelligence into Clinical Trial Analysis
CalciMedica entered into a strategic partnership with Telperian to utilize its AI-powered platform for in-depth analysis of clinical trial data for its lead drug candidate, Auxora™. This collaboration is intended to optimize future trial designs and better identify patient subpopulations, a move that generated significant positive investor interest and stock price momentum.
CalciMedica Secures up to $32.5 Million in Credit Facility to Extend Operational Runway and Fund Clinical Trials
CalciMedica entered into a credit facility agreement for up to $32.5 million, with an initial tranche of $10 million funded at closing. This strategic financing is intended to provide the company with the capital needed to fund its ongoing clinical trials for Auxora™ and extend its cash runway into mid-2026.
RATINGS SNAPSHOT
Overall rating: C-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 PDSB | $1.23 | COMPARE |
 RNXT | $1.48 | COMPARE |
 XLO | $9.26 | COMPARE |
 ELUT | $0.80 | COMPARE |
 LTRN | $0.93 | COMPARE |
 TVRD | $1.14 | COMPARE |
 RVPH | $0.51 | COMPARE |